title: Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice.
abstract: OBJECTIVE
  Skip inflammation of the appendiceal orifice has been described in distal UC (UC-IAO) but long-term clinical outcomes are poorly established. Our aim was to evaluate the long-term clinical outcomes of UC-IAO as compared to classic distal UC.
  
  
  METHODS
  Patients with UC-IAO were identified from the local IBD database. Disease outcome and therapeutic requirements during follow-up were accurately collected, and compared with a control group of patients with distal UC without peri-appendiceal involvement matched by disease extent (proctitis/distal), smoking habit, and date and age at diagnosis.
  
  
  RESULTS
  Fourteen UC patients were found to have UC-IAO, most of them with initial extent of UC limited to the rectum. All patients were initially managed with mesalazine administered orally (28.5%), topically (28.5%), or in combination (43%). After a median follow-up of 78 months (interquartile range--IQR 45-123) most UC-IAO patients were successfully managed with oral and/or topical aminosalicylates. Only one of them developed proximal disease progression. As compared to controls, no differences in clinical outcomes or therapeutic requirements were found.
  
  
  CONCLUSIONS
  Patients with UC-IAO tend to present a mild course, with a low probability to develop proximal progression of disease extent or to require immunosuppressive therapy or colectomy.
authors.affiliation: Germans Trias i Pujol University Hospital, Centro de Investigación Biomédica en red en Enfermedades Hepatica y Digestivas, Badalona, Spain.
authors.forename: Juan E
authors.initials: JE
authors.lastname: Naves
authors.forename: Vicente
authors.initials: V
authors.lastname: Lorenzo-Zúñiga
authors.forename: Laura
authors.initials: L
authors.lastname: Marín
authors.forename: Míriam
authors.initials: M
authors.lastname: Mañosa
authors.forename: Blanca
authors.initials: B
authors.lastname: Oller
authors.forename: Vicente
authors.initials: V
authors.lastname: Moreno
authors.forename: Yamile
authors.initials: Y
authors.lastname: Zabana
authors.forename: Jaume
authors.initials: J
authors.lastname: Boix
authors.forename: Eduard
authors.initials: E
authors.lastname: Cabré
authors.forename: Eugeni
authors.initials: E
authors.lastname: Domènech
mesh_terms: D000284:Administration, Oral; D000287:Administration, Topical; D000328:Adult; D000368:Aged; D000636:Aminosalicylic Acids / Q000008:administration & dosage; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage; D001064:Appendicitis / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D016009:Chi-Square Distribution; D003093:Colitis, Ulcerative / Q000150:complications* / Q000175:diagnosis / Q000188:drug therapy; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D019804:Mesalamine / Q000008:administration & dosage; D008875:Middle Aged; D012189:Retrospective Studies; D013030:Spain; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000636:Aminosalicylic Acids; D000893:Anti-Inflammatory Agents; D019804:Mesalamine